Transgenomic, Hoping to Win Time and Compliance, Asks Nasdaq to Be Transferred to Capital Market

Aug 02, 2006

NEW YORK (GenomeWeb News) – Transgenomic has asked the Nasdaq exchange to transfer its stock from the Global Market to the Capital Market in a bid to win time and regain compliance, according to documents filed with the Securities and Exchange Commission yesterday.

Transgenomic’s common stock does not meet Nasdaq's minimum $1 per share bid price to remain listed on the Global Market, the filing said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Best Options

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

A Butterfly's Wings

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

This Week in PNAS

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Pathogen Tracking

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.

Main menu